Astellas Culls Positions Ahead Of Big Expiry
Executive Summary
Astellas is looking to cut hundreds of positions in Japan as it faces a major upcoming patent expiry and refocuses under a new strategic plan.
You may also be interested in...
Strong Xtandi Drives Astellas To Brighter Outlook
Japanese firm unveils new capital investment program for novel biologics including antibodies and cell therapies as it ups full-year forecasts on strong US and global growth for Xtandi after a solid first half.
Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer
Protocol changes for the Phase III ARCHES and EMBARK trials will deliver results in hormone-sensitive prostate cancer a year and a half earlier than expected. Xtandi may then gain a valuable new indication sooner than anticipated, but generics for competitor Zytiga could launch before then.
Aquinox, Astellas Mull Options As Rosiptor Fails
Astellas’ late-stage bet on Aquinox’s urology drug now looks highly unlikely to pay off following the molecule’s “definitive” failure in a Phase III trial, which is also forcing the originator to consider its business and R&D options.